Nasdaq:ELTX
Elicio Therapeutics, Inc.
A pre-commercial biotechnology firm advancing innovative therapeutic candidates while burning substantial cash for R&D and capitalizing on financing activities.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock for exposure to high-potential biotechnology assets that could revolutionize treatment options for serious diseases if clinical trials succeed. The company's specialized drug delivery technology represents a moat that could yield significant returns upon successful regulatory approval and commercial launch of its therapeutic candidates.
Bear Case
The stock carries extreme risk due to zero revenue, a massive retained earnings deficit exceeding $194 million, and negative operating cash flow of $37.1 million indicating heavy cash burn. Without imminent partnership deals or successful phase transitions, the company faces potential dilution from share issuances or bankruptcy if it cannot secure additional capital quickly.
About Elicio Therapeutics, Inc.
Elicio Therapeutics is a biotechnology company focused on developing novel therapeutic candidates for serious diseases, leveraging proprietary drug delivery technologies. The company primarily operates in the specialized pharmaceutical market with revenue generated from clinical-stage research programs rather than commercial product sales. Key financial indicators highlight significant investment in research and development alongside a current operating cash deficit typical of early-stage biotech firms.
Analysis
Management Discussion
Despite a net loss of $51.9 million in 2024 driven by operating expenses of $45.0 million and substantial research and development spending of $33.7 million, the company successfully raised $42.3 million from financing activities. Cash and equivalents increased to $19.5 million ending balance, providing a runway to continue advancing its clinical pipeline despite the absence of commercial revenue.
Industry Overview
The biotechnology industry is characterized by long development cycles, high regulatory barriers, and significant upfront capital requirements before any commercial revenue is realized. Companies in this sector typically operate at a loss during the research and clinical trial phases while seeking to de-risk their pipelines through strategic collaborations or licensing agreements.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.3M | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $2.3M | $0 | $0 |
| Operating Expenses | $41.9M | $35.7M | $45.0M |
| Operating Income | $-39.6M | $-35.7M | $-45.0M |
| R&D | $18.1M | $23.8M | $33.7M |
| G&A | $14.6M | $11.9M | $11.3M |
| Stock-Based Comp | $885.0K | $1.2M | $1.5M |
| Depreciation | $178.0K | $382.0K | $321.0K |
| Other OpEx | $9.2M | $0 | $0 |
| Non-Operating Income | $823.0K | $0 | $0 |
| Interest Expense | — | $1.1M | — |
| Pre-Tax Income | $-38.8M | $-35.7M | $-45.0M |
| Income Tax | $11.0K | $0 | $0 |
| Continuing Ops | $-38.8M | $-35.7M | $-45.0M |
| Discontinued Ops | $2.0K | $0 | $0 |
| Net Income | $-38.8M | $-35.2M | $-51.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-38.8M | $-35.2M | $-51.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $51.4M | $16.3M | $20.7M |
| Cash & Equivalents | $50.5M | $12.9M | $17.6M |
| Prepaid Expenses | $943.0K | $2.7M | $1.9M |
| Other Current Assets | $0 | $722.0K | $1.2M |
| Long-Term Assets | $1.4M | $10.8M | $7.5M |
| PP&E (Net) | $273.0K | $717.0K | $483.0K |
| Operating Leases | $152.0K | $6.6M | $5.7M |
| Other LT Assets | $935.0K | $3.5M | $1.3M |
| Total Assets | $52.8M | $27.1M | $28.2M |
| Current Liabilities | $6.4M | $9.8M | $11.5M |
| Accounts Payable | $2.7M | $4.4M | $1.0M |
| Current Leases | $994.0K | $910.0K | $901.0K |
| Deferred Revenue | $0 | $694.0K | $1.2M |
| Other Current Liab | $86.0K | $36.0K | $0 |
| Long-Term Liabilities | $2.6M | $6.0M | $28.0M |
| LT Operating Leases | $2.5M | $6.0M | $5.1M |
| Other LT Liab | $168.0K | $0 | $22.9M |
| Total Liabilities | $9.0M | $15.8M | $39.5M |
| Shareholders' Equity | $43.8M | $11.4M | $-11.3M |
| Paid-In Capital | $297.3M | $153.8M | $183.0M |
| Retained Earnings | $-253.9M | $-142.2M | $-194.1M |
| AOCI | $86.0K | $-197.0K | $-175.0K |
| Total L&E | $52.8M | $27.1M | $28.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-38.8M | $-35.2M | $-51.9M |
| Non-Cash Adjustments | $7.2M | $3.3M | $21.7M |
| Working Capital Changes | $-6.7M | $-815.0K | $-6.8M |
| Cash from Operations | $-38.4M | $-32.7M | $-37.1M |
| Capital Expenditures | $0 | $66.0K | $87.0K |
| Cash from Investing | $0 | $-32.0K | $-84.0K |
| Cash from Financing | $-60.0K | $38.6M | $42.3M |
| FX Effect | $181.0K | $0 | $22.0K |
| Net Change in Cash | $-38.3M | $5.9M | $5.2M |
| Beginning Cash | $88.8M | $8.4M | $14.3M |
| Ending Cash | $50.5M | $14.3M | $19.5M |
Frequently Asked Questions
How does Elicio Therapeutics, Inc. make money?
The company's operations are concentrated in two primary segments: proprietary drug discovery and development focused on specific disease indications, and licensing or collaboration arrangements that provide non-revenue related financial support. Current financials show zero commercial revenue, with all activity directed toward advancing clinical candidates through the regulatory pathway.
What are the main risks for ELTX?
The primary risk is the company's reliance on external financing due to negative cash flows from operations and a significant accumulated deficit of over $194 million. Additional risks include the high volatility associated with clinical trial outcomes which could lead to total loss of invested R&D capital, as well as regulatory hurdles in bringing new therapies to market.
What is ELTX's competitive advantage?
Elicio Therapeutics maintains a competitive edge through its unique proprietary technology platforms designed to overcome biological barriers in drug delivery. The company's strategic advantage lies in its specialized expertise in targeting difficult-to-treat diseases where few therapeutic options currently exist, creating high potential value upon successful commercialization.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.